Xeljanz Lawsuit Investigation

FDA Warns Rheumatoid Arthritis Drug Linked To Blood Clots & Pulmonary Embolism

FDA Warns Xeljanz Linked To Blood Clots and Pulmonary Embolism

The FDA is alerting the public that a safety clinical trial found an increased risk of blood clots in the lungs, pulmonary embolism and death when a 10 mg twice daily dose of tofacitinib (sold under the brand name Xeljanz and Xeljanz XR) was used in patients with rheumatoid arthritis. The agency stated “the FDA has not approved this 10 mg twice daily dose for rheumatoid arthritis; this dose is only approved for patients with ulcerative colitis.”

What is Xeljanz?

Xeljanz (tofacitinib) is manufactured by Pfizer and was approved by the FDA for the treatment of moderate to severe rheumatoid arthritis (RA), particularly in patients that do not respond well to other forms of treatment. The drug works by blocking the enzymes responsible for the joint inflammation that RA patients suffer.

Xeljanz Blood Clot Symptoms

Patients taking Xeljanz should be aware of the symptoms of a blood clot or pulmonary embolism. Please seek medical attention immediately if you experience any of the following symptoms:

  • Difficulty breathing
  • Chest pain
  • Pain in upper back
  • Coughing up blood
  • Excessive sweating
  • Bluish skin

Now Investigating Xeljanz Blood Clot Lawsuit

The Justice Attorneys at Aylstock, Witkin, Kreis & Overholtz, PLLC are investigating the possibility of a lawsuit against the manufacturers of Xeljanz to determine if they knew about the increased risk of blood clotting disorders and should have notified patients about that risk. Contact our Xeljanz attorneys today for a free consultation. There is never a fee unless we recover for you.